BioSyent Expands Oral Health Portfolio with $25.5M Oral Science Acquisition
Event summary
- BioSyent Inc. to acquire Oral Science Inc. for $25.5M, including $22.5M in cash and 234,192 BioSyent shares.
- Transaction expected to close by late February 2026, with combined pro-forma revenue exceeding $70M and EBITDA over $15.75M (TTM Sept 30, 2025).
- Oral Science generated $30M in revenue and $4M in EBITDA for the TTM ended September 30, 2025.
- BioSyent financing includes $16.5M in cash and a $6M term loan from RBC Royal Bank.
- Oral Science will operate as a standalone business unit under BioSyent, maintaining its current leadership.
The big picture
BioSyent's acquisition of Oral Science represents a strategic move to diversify its product portfolio and revenue streams in the growing Canadian oral health market. The deal underscores a trend of consolidation in the specialty healthcare sector, with companies seeking to expand their market reach through targeted acquisitions. The transaction's financing structure, including a term loan from RBC Royal Bank, highlights BioSyent's strong balance sheet and confidence in the deal's accretive potential.
What we're watching
- Integration Challenges
- How BioSyent will manage the integration of Oral Science's diverse sales channels and product portfolio.
- Financial Performance
- Whether the acquisition will meet BioSyent's expectations for accretive growth and EBITDA expansion.
- Market Expansion
- The pace at which BioSyent can leverage Oral Science's platform to grow internationally.
Related topics